Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
06:16pm, Wednesday, 30'th Jul 2025
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $1.7 per share a year ago.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of S
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)
03:22pm, Tuesday, 01'st Jul 2025
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
What Makes Sage Therapeutics (SAGE) a New Buy Stock
01:01pm, Tuesday, 01'st Jul 2025
Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
07:59am, Monday, 23'rd Jun 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of S
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
03:41pm, Tuesday, 17'th Jun 2025
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
02:22pm, Tuesday, 17'th Jun 2025
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
12:10pm, Tuesday, 17'th Jun 2025
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect
10:00am, Tuesday, 17'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company")
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
05:31pm, Monday, 16'th Jun 2025
NEW YORK , June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board of directors concerning the propos
SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders
09:10am, Monday, 16'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage
Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.
07:42am, Monday, 16'th Jun 2025
The deal is worth an initial $561 million, with potential for $234 million in add-ons.
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Cl
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
07:14am, Monday, 16'th Jun 2025
Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.
